NCT04824144View on ClinicalTrials.gov

Effects of Dexmedetomidine in Patients With Agitated Delirium in Palliative Care

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 30, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions
Hyperactive DeliriumDelirium of Mixed Origin
Interventions
DRUG

Dexmedetomidine Hydrochloride

Dexmedetomidine will be administered by subcutaneous continuous infusion using a Continuous Ambulatory Delivery Device (CADD pump).

Trial Locations (3)

T2N 2T9

RECRUITING

Foothills Medical Centre, Calgary

K1H 8L6

RECRUITING

The Ottawa Hospital, Ottawa

K1N 5C8

RECRUITING

Bruyère Continuing Care, Ottawa

Sponsors

Collaborators (1)

Foothills Medical Centre
All Listed Sponsors
collaborator

The Ottawa Hospital

OTHER

collaborator

Bruyère Continuing Care

UNKNOWN

collaborator

Foothills Medical Centre

OTHER

lead

Bruyère Health Research Institute.

OTHER